ID 原文 译文
1107 在治疗期间须密切监测患者症状、体征、血常规、C反应蛋白、降钙素原等指标，出现病情变化须临床综合判断， The patient’s symptoms, signs and indicators such as blood routine, C-reactive protein, and procalcitonin, need to be closely monitored during the treatment. When the change of a patient’s condition is detected, a comprehensive clinical judgment needs to be made.
1108 在不能排除继发感染时须第一时间留取合格标本进行涂片、培养，进行核酸、抗原抗体检测以便尽早明确感染病原体。 When the secondary infection cannot be ruled out, qualified specimen need to be collected for testing by smear preparation, cultivation, nucleic acid, antigen and antibody, in order to determine the infectious agent as early as possible.
1109 出现下述情况可经验性使用抗菌药物：①咳痰增多、痰液颜色变深，尤其是出现黄脓痰；②体温升高，且不能用原发疾病加重解释；③白细胞、中性粒细胞数显著增多；④降钙素原≥ 0.5ng/mL；⑤病毒感染无法解释的氧合指数恶化或循环障碍及其他提示细菌感染的病情改变。 Antibiotics can be empirically used in the following conditions: ① more expectoration, darker sputum color, especially yellow pus sputum; ② the rise of body temperature which is not due to exacerbation of the original disease; ③ the marked increase of white blood cell s and/or neutrophil s; ④ procalcitonin ≥ 0.5 ng/mL; ⑤ Exacerbation of oxygenation index or circulator y disturbance that are not caused by the viral infection; and the other conditions suspiciously caused by bacteria infections.
1110 病毒感染造成细胞免疫功能下降、糖皮质激素和/或广谱抗菌药物使用等因素导致部分COVID-19患者有继发真菌感染风险，须对危重患者行呼吸道分泌物微生物监测，包括涂片、培养；对可疑患者及时检测血或支气管肺泡灌洗液D-葡聚糖（G试验）、半乳甘露聚糖（GM试验）。 Some COVID-19 patients are at the risk of secondary fungal infections due to weakened cellular immunity caused by viral infections, the use of glucocorticoid and/or broad-spectrum antibiotics. It is necessary to do Respiratory secretions microbiological detections such as smear preparation and cultivation for critically ill patients; and provide timely D-Glucose (G-test) and galactomannan (GM-test) of blood or bronchoalveolar lavage fluid for suspected patients.
1111 以下患者须警惕侵袭性念珠菌病，可考虑给予氟康唑或棘白菌素类抗真菌治疗： It is necessary to be vigilant with possible invasive candidiasis infection and anti-fungal therapy.
1112 ①广谱抗菌药物使用7天及以上；②胃肠外营养；③ 接受有创检查或治疗；④两个或以上部位来源的标本培养念珠菌阳性；⑤G实验明显升高。 Fluconazole or echinocandin can be used in the following conditions: ① patients are given broad-spectrum antibiotics for seven days or more; ② patients have parenteral nutrition; ③ patients have invasive examination or treatment; ④ patients have positive candida culture in the specimen obtained from two body part s or more; ⑤ patients have significantly increased result s of G-test.
1113 以下患者须警惕侵袭性肺曲霉病， It is necessary to be vigilant with possible invasive pulmonary aspergillosis.
1114 可考虑给予伏立康唑、泊沙康唑或棘白菌素类治疗：①糖皮质激素使用7天及以上；②粒细胞减少或缺乏；③慢性阻塞性肺病且既往气道标本培养曲霉阳性；④GM明显升高。 Anti-fungal therapy such as voriconazole, posaconazole, or echinocandin are considered to be used in the following conditions: ① patients are given glucocorticoid for seven days or more; ② patients have agranulocytosis; ③ patients have chronic obstructive pulmonary disease and aspergillus culture are tested positive in the specimen obtained from the airway; ④ patients have significantly increased result s of GM-test.
1115 九. 肠道微生态平衡营养支持 IX. The Balance of Intestinal Microecology and Nutritional Support
1116 COVID-19患者由于病毒直接侵犯肠道黏膜、抗病毒抗感染等治疗药物影响，部分患者合并腹痛、腹泻等消化道症状。 Some COVID-19 patients have gastrointestinal symptoms (such as abdominal pain and diarrhea) due to direct viral infection of the intestinal mucosa or antiviral and anti-infective drugs.